Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Novo Nordisk NOVO.B2.14%increase; green up pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human ...

(Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using ...

Novo Nordisk expands Valo partnership, increasing eligible milestone payments to $4.6 billion for up to 20 drug programs. Variant Bio to receive $50 million upfront and R&D funding in Novo Nordisk ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

Novo Nordisk pays $60M for 3 preclinical assets as part of AI-powered cardio collab with Valo “While the data were intrigu­ing, OPL-0401 did not incor­po­rate ele­ments of our plat­form in ...

Novo Nordisk is planning to open an artificial intelligence ... In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery ...

Novo Nordisk is expanding its collaboration with the U.S.-based technology company, Valo Health. This partnership aims to accelerate the development of new treatments for obesity, cardiovascular ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...